On July 13, 2026, the FDA approved at-home Leqembi — lecanemab-irmb — shots as a starting treatment for early Alzheimer's. Patients or caregivers can now give the first doses with an autoinjector, with no required months of IV infusions to begin.
The option applies to adults with mild cognitive impairment or mild dementia due to Alzheimer's who have confirmed amyloid buildup. Drug Topics reports that amyloid-beta pathology must be confirmed before treatment. Until this change, Patient Care Online notes, the weekly autoinjector was allowed only after 18 months of clinic IV therapy.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Apply through Biospace’s official page — Use this page to review requirements and apply directly.
Table of Contents
- What changed in July 2026?
- Who is the at-home start for?
- How do at-home shots and IV infusions compare?
- What does the evidence show — and not show?
- What safety checks still apply at home?
What changed in July 2026?
Eisai/Biogen via BioSpace announced the July 13, 2026 approval of once-weekly subcutaneous lecanemab-irmb, called LEQEMBI IQLIK, as an initiation dose for early Alzheimer's approval announcement. The decision lets patients or caregivers give starting doses at home with an autoinjector. Drug Topics reports this ends the prior rule that treatment must start with clinic IV infusions.
The usual IV start was 10 mg/kg every two weeks over 18 months. Drug Topics notes that schedule was tested in two randomized trials in amyloid-confirmed early disease. The weekly home device had served only as maintenance after at least 18 months of IV care, according to Patient Care Online.
Who is the at-home start for?
Drug Topics reports the group is adults with mild cognitive impairment or mild dementia due to Alzheimer's. These labels describe early problems with memory, thinking, or daily tasks from Alzheimer's.
Treatment still requires confirmed amyloid-beta pathology, meaning plaque buildup shown by testing, before the first dose. Ask the clinic what test proves amyloid status in your case. A home start does not expand the stage or skip that proof.
- mild cognitive impairment or mild dementia linked to Alzheimer's
- confirmed amyloid-beta pathology before treatment
- a patient or caregiver able to give weekly autoinjector doses at home
How do at-home shots and IV infusions compare?
Drug Topics summarizes the IV start as 10 mg/kg given every two weeks in a clinic over 18 months treatment summary. The home start uses once-weekly shots given under the skin with an autoinjector.
Patients or caregivers give those shots outside the infusion clinic. Families often weigh travel, schedules, and comfort with shots. Review those practical trade-offs with the prescribing team before choosing a start.
- clinic IV: 10 mg/kg every two weeks, given by staff in clinic
- home shot: once-weekly autoinjector, given by patient or caregiver
- either start needs confirmed amyloid-beta before dosing
What does the evidence show — and not show?
In phase 3 CLARITY AD with 1,795 participants, Drug Topics reports IV lecanemab differed from placebo by −0.45 points on CDR-SB at 18 months. CDR-SB is a dementia severity score, so a lower score means less decline. The same report notes substantial amyloid reduction.
Subcutaneous starting doses did not have their own outcomes trial. Drug Topics reports approval rested on IV results plus matching drug exposure and similar plaque clearance. That link supports use but does not equal direct proof that home starts slow decline by the same amount.
What safety checks still apply at home?
Home dosing does not drop brain-safety checks. The FDA safety communication recommends one added earlier MRI before the third infusion to look for ARIA-E swelling safety notice. ARIA-E means fluid or swelling in the brain seen on scans. The same FDA notice calls for ApoE-ε4 testing and bleeding-risk review.
ApoE-ε4 is a gene marker used in safety planning, while bleeding risk affects treatment decisions. Both checks happen alongside MRI monitoring. Keep infusion-center and scan dates even after switching to shots. Ask the prescribing clinic how MRI visits, gene testing, and bleeding review will be timed before the first home dose.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: What the News Means for People With Early Alzheimer’s
- Cross-Cultural Dementia Risk Programs After LatAm-FINGERS 2026: What the Update Means for Adults in Midlife
- Healthy Diets in the 2026 WHO Dementia Guideline: How the Advice Compares With Common Online Claims for Adults Over 65
